

# Clinical trials of extended nadroparin

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
<b>extended nadroparin vs standard treatment</b>			
<a href="#">Lopez Beret , 2001</a> n=NA follow-up: 12 months	Nadroparin 1.025 antiXa IU/10Kg twice daily after aadroparin 1.025AXa IU/10Kg twice daily for 3 days. After 3 months, nadroparin was switched to once daily versus acenocoumarol (target INR 2-3) for 3-6 months after nadroparin 1.025AXa IU/10Kg twice daily for 3 days	patients with known malignancy treated for symptomatic DVT of the lower limb	Parallel groups outcome assessment blinded

More details and results :

- antithrombotics for venous thrombosis in patients with cancer at <http://www.trialresultscenter.org/go-Q103>

## References

### Lopez Beret, 2001:

Lpez-Beret P, Orgaz A, Fontcuberta J, Doblaz M, Martinez A, Lozano G, Romero A Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001;33:77-90 [[11137927](#)]

Entry terms: nadroparin, Nadroparine, Fraxiparin, Fraxiparine, CY 216, CY-216, CY216, LMF CY-216, LMF CY 216, LMF CY216,